Related references
Note: Only part of the references are listed.Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ, agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes
Marika Massaro et al.
PHARMACOLOGICAL RESEARCH (2016)
The First Approved Agent in the Glitazar's Class: Saroglitazar
Ritesh Agrawal
CURRENT DRUG TARGETS (2014)
Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Bertrand Cariou et al.
DIABETES CARE (2013)
Fenofibrate, a peroxisome proliferator-activated receptor a agonist, alters triglyceride metabolism in enterocytes of mice
Aki Uchida et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2011)
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
Bertrand Cariou et al.
DIABETES CARE (2011)
Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients During an Oral Fat Load
G. Derosa et al.
HORMONE AND METABOLIC RESEARCH (2011)
Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: A role for PPAR-gamma pathway
Jasmin Khateeb et al.
ATHEROSCLEROSIS (2010)
Effects of Thiazolidinediones and Sulfonylureas in Patients with Diabetes
Giuseppe Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2010)
Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus Comparison with Other Oral Antihyperglycaemic Agents
Giuseppe Derosa
DRUGS (2010)
Oral Glucose Tolerance Test Effects on Endothelial Inflammation Markers in Healthy Subjects and Diabetic Patients
G. Derosa et al.
HORMONE AND METABOLIC RESEARCH (2010)
Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients
G. Derosa et al.
HORMONE AND METABOLIC RESEARCH (2010)
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin
G. Derosa et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects
Giuseppe Derosa et al.
MICROVASCULAR RESEARCH (2010)
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects
Giuseppe Derosa et al.
MICROVASCULAR RESEARCH (2010)
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
Giuseppe Derosa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PPARs and the Cardiovascular System
Milton Hamblin et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment
Giuseppe Derosa et al.
BIOMEDICINE & PHARMACOTHERAPY (2009)
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
Giuseppe Derosa et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects
Giuseppe Derosa et al.
HEART AND VESSELS (2009)
Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine
Giuseppe Derosa et al.
INTERNAL MEDICINE (2009)
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
Robert R. Henry et al.
LANCET (2009)
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study
Giuseppe Derosa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease
Sho-ichi Yamagishi et al.
PHARMACOLOGICAL RESEARCH (2009)
Comparison of effects of Simvastatin alone versus Fenofibrate alone versus Simvastatin plus Fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the diabetes and combined lipid therapy regimen study)
Heidi T. May et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Regulatory functions of PPARβ in metabolism:: Implications for the treatment of metabolic syndrome
Paul A. Grimaldi
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin
G. Derosa et al.
INTERNAL MEDICINE JOURNAL (2007)
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
Jonathan D. Brown et al.
CIRCULATION (2007)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
Liliane Michalik et al.
PHARMACOLOGICAL REVIEWS (2006)
Antihypertensive effect of ragaglitazar:: A novel PPARα and γ dual activator
Prem K. Mamnoor et al.
PHARMACOLOGICAL RESEARCH (2006)
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy
DM Kendall et al.
DIABETES CARE (2006)
Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes
S Luquet et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2005)
Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance
JR Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes
PW Peake et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study
DR Matthews et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial)
SM Grundy et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Alexander Tenenbaum et al.
CARDIOVASCULAR DIABETOLOGY (2005)
An overview on biological mechanisms of PPARs
BP Kota et al.
PHARMACOLOGICAL RESEARCH (2005)
Oral antidiabetic agents - Current role in type 2 diabetes mellitus
AJ Krentz et al.
DRUGS (2005)
Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease
J Bassaganya-Riera et al.
GASTROENTEROLOGY (2004)
The role of sulphonylureas in the management of type 2 diabetes mellitus
M Rendell
DRUGS (2004)
Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo -: A study using the novel PPARα/γ agonist tesaglitazar
BD Hegarty et al.
ENDOCRINOLOGY (2004)
Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity
S Giannini et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Peroxisome proliferator-activated receptors and atherogenesis - Regulators of gene expression in vascular cells
N Marx et al.
CIRCULATION RESEARCH (2004)
Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors
CH Lee et al.
ENDOCRINOLOGY (2003)
Metformin - New understandings, new uses
RS Hundal et al.
DRUGS (2003)
Sulfonylurea stimulation of insulin secretion
P Proks et al.
DIABETES (2002)
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
T Meade et al.
BRITISH MEDICAL JOURNAL (2002)
Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
JA Beckman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity
BB Lohray et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study
D Einhorn et al.
CLINICAL THERAPEUTICS (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
